Cataplexy – Talk Bio

Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton

4 days ago talkbio0Tagged alixorexton, Alkermes, Cataplexy, Daytime Somnolence, Excessive (qualifier value), late-stage testing, Narcolepsy, Narcolepsy type 1, normative wakefulness, Orexin Receptor Agonist, Vibrance-1 study

Alkermes; narcolepsy; alixorexton; Phase 2 trial; orexin 2 receptor agonist; narcolepsy type 1; normative wakefulness; late-stage testing; Vibrance-1 study; cataplexy; excessive daytime sleepiness

FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients

9 months ago talkbio0Tagged Approved, Avadel, Cataplexy, Daytime Somnolence, Excessive (qualifier value), Excessive Daytime Sleepiness, LUMRYZ, Narcolepsy, Pediatric brand name, sodium oxybate, United States Food and Drug Administration

Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)

Axsome Therapeutics’ Small Molecule AXS-12 Successful in Phase III Narcolepsy Trial

1 year ago talkbio0Tagged AXS-12, Axsome, Cataplexy, Drowsiness, Improved, memory/, Narcolepsy, Phase 3 Clinical Trials, reboxetine, safety profile, Severities

Axsome Therapeutics, AXS-12 (reboxetine), Phase III trial, Narcolepsy, Cataplexy reduction, Improved cognition/ memory/ sleepiness severity, Safety profile